Labcorp, Children's Hospital of Philadelphia Partner on Pediatric Diagnostics

The collaboration will create a joint pipeline to develop and commercialize specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.

Children’s Hospital of Philadelphia and Labcorp on Monday announced a strategic collaboration to accelerate the development and national distribution of specialized pediatric diagnostics.

“By combining CHOP’s deep pediatric expertise with Labcorp’s scientific capabilities and national reach, we can bring pediatric diagnostic innovations to patients faster and make advanced testing accessible to many more families,” Bryan Vaughn, Labcorp executive VP of Diagnostics, said in a statement.

At the center of the agreement is a joint pediatric diagnostics innovation pipeline through which the two organizations will identify, develop, and scale new tests and technologies. The partners will initially focus on oncology, metabolic disease, and autoimmune conditions. No financial terms were disclosed.

Pediatric-specific diagnostics are designed to account for children’s distinct biology, developmental stages and physiological ranges, factors that adult-oriented tests do not typically address.